| Literature DB >> 32106464 |
Maryamsadat Shokrekhodaei1, Stella Quinones2.
Abstract
Annual deaths in the U.S. attributed to diabetes are expected to increase from 280,210 in 2015 to 385,840 in 2030. The increase in the number of people affected by diabetes has made it one of the major public health challenges around the world. Better management of diabetes has the potential to decrease yearly medical costs and deaths associated with the disease. Non-invasive methods are in high demand to take the place of the traditional finger prick method as they can facilitate continuous glucose monitoring. Research groups have been trying for decades to develop functional commercial non-invasive glucose measurement devices. The challenges associated with non-invasive glucose monitoring are the many factors that contribute to inaccurate readings. We identify and address the experimental and physiological challenges and provide recommendations to pave the way for a systematic pathway to a solution. We have reviewed and categorized non-invasive glucose measurement methods based on: (1) the intrinsic properties of glucose, (2) blood/tissue properties and (3) breath acetone analysis. This approach highlights potential critical commonalities among the challenges that act as barriers to future progress. The focus here is on the pertinent physiological aspects, remaining challenges, recent advancements and the sensors that have reached acceptable clinical accuracy.Entities:
Keywords: Raman; absorption; bioimpedance; breath acetone; diabetes; glucose; non-invasive; optical; polarimetry; scattering
Mesh:
Substances:
Year: 2020 PMID: 32106464 PMCID: PMC7085605 DOI: 10.3390/s20051251
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Figure 1Non-invasive glucose sensing techniques.
Figure 2Non-Invasive glucose measurement techniques based on glucose and tissue/blood properties.
Figure 3Skin tissue layers.
Figure 4Types of Interactions between Light (Photons) and Tissue.
Figure 5A simplified schematic illustrating transmission absorption spectroscopy.
Figure 6A simplified schematic illustrating polarimeter.
Figure 7A simplified schematic illustrating Raman spectroscopy.
Figure 8A simplified schematic illustrating scattering spectroscopy of a (a) low glucose concentration tissue sample versus a (b) high glucose concentration tissue sample.
Figure 9A simplified schematic illustrating optical coherence tomography of tissue.
Figure 10(a) A simplified schematic illustrating tissue impedance spectroscopy, (b) An electrical model for a single red blood cell.
Figure 11A simplified schematic illustrating a reflection mode EM measurement.
Summary of studies that report a negative correlation between breath acetone and blood glucose concentration.
| Ref | Type of Patient, | Instrumentation for Measuring Blood Glucose | Insulin Injection/Infusion Treatment | Control of Food Intake | Type of Meas. (Duration) | Correlation of Breath Acetone with Blood Glucose Concentration | Acetone Meas. Technique |
|---|---|---|---|---|---|---|---|
| [ | T1D, | Standard Diabetic Management BG meter (Roche, Switzerland) | No history of treatment | No information available during continuous monitoring | Continuous monitoring | Negative correlation in each subject | Cavity Ringdown Spectroscopy |
| [ | T1D, | Blood glucose and ketone monitoring system kit (Optium Xceed, Abbott, USA) | Insulin therapy | 4 h of fasting | Single measurement | Weak negative correlation when T1D subjects were ungrouped (Pearson’s R = −0.13); | Cavity Ringdown Spectroscopy |
| [ | Non-diabetic, | Using Precision Xtra, electrochemical capillary blood monitor from Abbott, and glucose strips, | No information available | on 1st day, isocaloric meals were given to each subject for breakfast lunch and dinner; | Continuous monitoring | Negative nonlinear correlation for all subjects (glucose decreases and breath acetone increases); | Selected Ion Flow Tube-Mass Spectrometry |
| [ | T1D, | Accu-Chek Active (Roche Diagnostics, Berlin, Germany) | No information available | No information available | Continuous monitoring | Negative correlation in each subject | Commercial acetone gas sensor (TGS 822, 823 Figaro, Arlington Heights, IL, USA Inc) |
Summary of studies that report a positive correlation between breath acetone and blood glucose concentration.
| Ref | Type of Patient, | Instrumentation for Measuring Blood Glucose | Insulin Injection/Infusion Treatment | Control of Food Intake | Type of Meas. (Duration) | Correlation of Breath Acetone with Blood Glucose Concentration | Acetone Meas. Technique |
|---|---|---|---|---|---|---|---|
| [ | T1D, | Intravenous catheter used for blood sampling and hand was warmed to 55C to “arterialize” the venous sample, OGTT performed | Insulin infusion to create hypoglycemia state | Overnight fast | Continuous monitoring | Positive correlation in each subject (glucose and acetone decrease) (R2 = 0.85, R2 = 0.88, R2 = 0.90, R2 = 0.78, R2 = 0.60, R2 = 0.86, R2 = 0.94, R2 = 0.71) | Selected Ion Flow Tube-Mass Spectrometry |
| [ | T1D, | Standard Self-Management BG meter owned by each patient | Under insulin treatment by wearing an insulin pump | No control | Single measurement per person | Positive correlation between the mean group acetone and the mean group blood glucose level when T1D subjects are grouped by different blood glucose level (R = 0.98, P < 0.02) | Cavity Ringdown Spectroscopy |
| [ | T1D, | Standard Self-Management BG meter owned by each patient | Under insulin treatment by wearing an insulin pump | Monitoring of food intake during a 24-h test | Continuous monitoring | Weak positive correlation in 2 T1D subjects (glucose and acetone peak at food intake, and then glucose and acetone decrease); | Cavity Ringdown Spectroscopy |
| [ | T1D, | Standard Diabetic Management BG meter (Roche, Switzerland) | No information available | Measurements were done in 4 different testing conditions: 14 h fast and 2-h post meals (breakfast, lunch and dinner) | Single measurement per person (4 samples taken for each subject under different testing condition) | Weak positive correlation between the mean individual breath acetone and the mean individual blood glucose levels in T1D subjects | Developed breath acetone analyzer based on the Cavity Ringdown Spectroscopy |
| [ | T1D, | Standard Diabetic Management BG meter (Roche, Switzerland) | Insulin injected for five days, Measurements were done in third and fifth day | No information available during continuous monitoring | Single measurement in the third and fifth day | Weak positive correlation in T1D subjects | Cavity Ringdown Spectroscopy |
| [ | T2D, | No information available | No information available | 8 h of fasting | Single measurement per person | Weak positive correlation | Gas Chromatography/Mass Spectrometry coupled with Solid Phase Micro-Extraction technique |
| [ | Non-diabetic, | Intravenous catheter was inserted into basilic vein, OGTT performed | No insulin injection; Serum insulin levels were measured in all subjects and then average values were calculated; | Overnight fast | Continuous monitoring | Weak positive correlation in each subject; | Gas Chromatography/Mass Spectrometry |
Summary of studies that report no correlation between breath acetone and blood glucose concentration.
| Ref | Type of Patient, | Instrumentation for Measuring Blood Glucose | Insulin Injection/Infusion Treatment | Control of Food Intake | Type of Meas. (Duration) | Correlation of Breath Acetone with Blood Glucose Concentration | Acetone Meas. Technique |
|---|---|---|---|---|---|---|---|
| [ | T1D, | Standard Diabetic Management BG meter (Roche, Switzerland) | No information available | Measurements were done in 4 different testing condition: 14 h fast and 2-h post meals (breakfast, lunch and dinner) | Single measurement per person (4 samples taken for each subject under different testing condition) | No clear correlation between the individual breath acetone and the individual blood glucose level in T1D, T2D and healthy subjects | Developed breath acetone analyzer based on the Cavity Ringdown Spectroscopy |
| [ | T2D, | No information available | No information available | 10-h fasting (no eating during the experiment) | Single measurement every hour for 2.5 h (0 h (initial measurement), 1 h, 2 h) in all group | No clear correlation at any time (0 h,1 h,2 h) between individual breath acetone and individual blood glucose level in all groups | Ion-molecule-Reaction Mass Spectrometer (V&F Analysen and Messtechnik GmbH, Austria) |
| [ | T2D, | Standard Diabetic Management BG meter (Roche, Switzerland) | No information available | Measurements were done in 4 different testing condition: 14 h fast and 2-h post meals (breakfast, lunch and dinner) | Single measurement per person (4 samples taken for each subject under different testing condition) | No clear correlation at any condition between individual breath acetone and individual blood glucose level in T2D and healthy subjects | Cavity Ringdown Spectroscopy |
| [ | T1D, | Glucose meter (Bayer Contour Link) | Insulin Dispensers (2 of subjects who were minors) and manual insulin injection (1 Adult) | Overnight fast | Single measurement | No clear correlation in T1D subjects | Quantum Cascade Laser Spectroscopy |
| [ | T2D, | Abbot Optium Xceed | Various Treatment: | No fasting and no eating one hour before the test | Single measurement per person | No correlation in T2D subjects | Selected Ion Flow Tube-Mass Spectrometry |
| [ | T1D, | Standard Diabetes Monitoring Meter (Abbott Diabetes Care Ltd., UK, FreeStyle Optium) | No information available | Minimum 8 h overnight fast | Single measurement once per day for 30 days | No clear correlation between the mean individual blood glucose and the mean individual breath acetone in T1D subjects (R = 0.17, P = 0.43) | Developed breath acetone analyzer based on the Cavity Ringdown Spectroscopy |
* Impaired glucose tolerance, ** Impaired fasting glycaemia, *** Reactive hypoglycemia.
Summary of fully non-invasive glucose sensors commercially available or under development based on the techniques reviewed in this paper.
| Non-invasive Device | Technology | Company | Meas. Area | Description | Ref |
|---|---|---|---|---|---|
| TensorTip Combo Glucometer | VIS-NIR spectroscopy | Cnoga Medical Ltd. (Israel) | Fingertip | State: approved for use in numerous countries worldwide; | [ |
| Wizmi | NIR spectroscopy | Wear2b Ltd. (Israel) | Wrist | State: Proof of concept acquisition; | [ |
| LTT device developed by the research group of Quantum Science and Technology | MIR spectroscopy | Light Touch Technology Ltd. (Japan) | Finger | State: Under development; | [ |
| Biovotion | Bioimpedance Spectroscopy | Biovotion Ltd. (Switzerland) | Arm | State: proof of concept acquisition; | [ |
| GlucoWise | Millimeter wave spectroscopy, nanocomposite technology | MediWise Ltd. (UK) | Between the thumb and forefinger | State: under development; | [ |